Abstract
Objective: The objective of this study is to evaluate the effect of diagnostic ureterorenoscopy (URS) prior to radical nephroureterectomy (RNU) on intravesical recurrence (IVR), in patients with primary upper urinary tract urothelial carcinoma (UTUC). Materials and Methods: Retrospective analysis of 354 patients, who underwent RNU for UTUC from 10 urology centers between 2005 and 2019, was performed. The primary endpoint was the occurrence of IVR after RNU. Patients were divided into URS prior to RNU (Group 1) and no URS prior to RNU (Group 2). Rates of IVR after RNU were compared, and a Cox proportional hazards model was used to evaluate potential predictors of IVR. Results: After exclusion, a total of 194 patients were analyzed: Group 1 n = 95 (49.0%) and Group 2 n = 99 (51.0%). In Group 1, a tumor biopsy and histopathological confirmation during URS were performed in 58 (61.1%). The mean follow-up was 39.17 ± 39.3 (range 12–250) months. In 54 (27.8%) patients, IVR was recorded after RNU, and the median recurrence time within the bladder was 10.0 (3–144) months. IVR rate was 38.9% in Group 1 versus 17.2% in Group 2 (p = 0.001). In Group 1, IVR rate was 43.1% in those undergoing intraoperative biopsy versus 32.4% of patients without biopsy during diagnostic URS (p =0.29). Intravesical recurrence-free survival (IRFS) was longer in Group 2 compared to Group 1 (median IRFS was 111 vs. 60 months in Groups 2 and 1, respectively (p< 0.001)). Univariate analysis revealed that IRFS was significantly associated with URS prior to RNU (HR: 2.9, 95% CI 1.65–5.41; p < 0.001). In multivariate analysis, URS prior to RNU (HR: 3.5, 95% CI 1.74–7.16; p < 0.001) was found to be an independent prognostic factor for IRFS. Conclusion: Diagnostic URS was associated with the poor IRFS following RNU for primary UTUC. The decision for a diagnostic URS with or without tumor biopsy should be reserved for cases where this information might influence further treatment decisions.
References
1.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer statistics, 2016
. CA Cancer J Clin
. 2018
;66
(1
):7
–30
. .20182.
Soria
F
, Shariat
SF
, Lerner
SP
, Fritsche
HM
, Rink
M
, Kassouf
W
, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
. World J Urol
. 2017 Mar
;35
(3
):379
–87
. .3.
Rouprtet
M
, Babjuk
M
, Comperat
E
, Zigeuner
R
, Sylvester
RJ
, Burger
M
, et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2017 update
. Eur Urol Focus
. 2018
;73
:111
–22
.4.
Tanaka
N
, Kikuchi
E
, Kanao
K
, Matsumoto
K
, Shirotake
S
, Kobayashi
H
, et al. Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma
. Ann Surg Oncol
. 2014
;21
(9
):3151
–8
. .5.
Wu
WJ
, Ke
HL
, Yang
YH
, Li
CC
, Chou
YH
, Huang
CH
. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
J Urol
. 2010
;183
(1
):56
–61
. .6.
Xylinas
E
, Colin
P
, Audenet
F
, Phe
V
, Cormier
L
, Cussenot
O
, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study
. World J Urol
. 2013
;31
(1
):61
–8
. .7.
Zigeuner
RE
, Hutterer
G
, Chromecki
T
, Rehak
P
, Langner
C
. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location
. BJU Int
. 2006
;98
(6
):1181
–6
. .8.
Seisen
T
, Granger
B
, Colin
P
, Léon
P
, Utard
G
, Renard-Penna
R
, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma
. Eur Urol
. 2015
;67
(6
):1122
–33
. .9.
Chitale
S
, Mbakada
R
, Irving
S
, Burgess
N
. Nephroureterectomy for transitional cell carcinoma: the value of pre-operative histology
. Ann R Coll Surg Engl
. 2008
;90
(1
):45
–50
. .10.
Guarnizo
E
, Pavlovich
CP
, Seiba
M
, Carlson
DL
, Vaughan
ED
Jr, Sosa
RE
. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach
. J Urol
. 2000
;163
(1
):52
–5
. .11.
Ishikawa
S
, Abe
T
, Shinohara
N
, Harabayashi
T
, Sazawa
A
, Maruyama
S
, et al. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract
. J Urol
. 2010 Sep
;184
(3
):883
–7
. .12.
Marchioni
M
, Primiceri
G
, Cindolo
L
, Hampton
LJ
, Grob
MB
, Guruli
G
, et al. Impact of diagnostic ureteroscopy on intra vesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis
. BJU Int
. 2017
;120
:313
–9
.13.
Guo
RQ
, Hong
P
, Xiong
GY
, Zhang
L
, Fang
D
, Li
XS
, et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis
. BJU Int
. 2018
;121
(2
):184
. .14.
Andersen
JR
, Kristensen
JK
. Ureteroscopic management of transitional cell tumors
. Scand J Urol Nephrol
. 1994
;28
(2
):153
–7
. .15.
Grasso
M
, McCue
P
, Bagley
DH
. Multiple urothelial recurrences of renal cell carcinoma after initial diagnostic ureteroscopy
. J Urol
. 1992
;147
(5
):1358
–60
. .16.
Shiraishi
K
, Eguchi
S
, Mohri
J
, Kamiryo
Y
. Role of ureteroscopic biopsy in the management of upper urinary tract malignancy
. Int J Urol
. 2003
;10
(12
):627
–30
. .17.
Hendin
BN
, Streem
SB
, Levin
HS
, Klein
EA
, Novick
AC
. Impact of diagnostic ureteroscopy on long-term survival in patients with upper tract transitional cell carcinoma
. J Urol
. 1999
;161
(3
):783
–5
. .18.
Habuchi
T
, Takahashi
R
, Yamada
H
, Kakehi
Y
, Sugiyama
T
, Yoshida
O
. Metachronous multifocal development of urothelial cancers by intraluminal seeding
. Lancet
. 1993
;342
(8879
):1087
–8
. .19.
Jones
TD
, Wang
M
, Eble
JN
, MacLennan
GT
, Lopez-Beltran
A
, Zhang
S
, et al. Molecular evidence supporting field effect in urothelial carcinogenesis
. Clin Cancer Res
. 2005 Sep 15
;11
(18
):6512
–9
. .20.
Takahashi
T
, Kakehi
Y
, Mitsumori
K
, Akao
T
, Terachi
T
, Kato
T
, et al. Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors
. J Urol
. 2001 Feb
;165
(2
):672
–7
. .21.
Hafner
C
, Knuechel
R
, Stoehr
R
, Hartmann
A
. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies
. Int J Cancer
. 2002 Sep 1
;101
(1
):1
–6
. . Review.22.
Miyake
H
, Hara
I
, Kamidono
S
, Eto
H
. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns
. J Urol
. 2004 Sep
;172
(3
):1127
–9
. .23.
Hafner
C
, Knuechel
R
, Zanardo
L
, Dietmaier
W
, Blaszyk
H
, Cheville
J
, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract
. Oncogene
. 2001 Aug 9
;20
(35
):4910
–5
. .24.
Lim
DJ
, Shattuck
MC
, Cook
WA
. Pyelovenous lymphatic migration of transitional cell carcinoma following flexible ureterorenoscopy
. J Urol
. 1993
;149
(1
):109
. .25.
Nison
L
, Rouprêt
M
, Bozzini
G
, Ouzzane
A
, Audenet
F
, Pignot
G
, et al. The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database
. World J Urol
. 2013 Feb
;31
(1
):69
–76
. .26.
Lee
HY
, Yeh
HC
, Wu
WJ
, He
JS
, Huang
CN
, Ke
HL
, et al. The diagnostic ureteroscopy before radical nephroureterectomy in upper urinary tract urothelial carcinoma is not associated with higher intravesical recurrence
. World J Surg Oncol
. 2018
;16
(1
):135
. .27.
Yoo
S
, You
D
, Song
C
, Hong
B
, Hong
JH
, Kim
CS
, et al. Risk of intravesical recurrence after ureteroscopic biopsy for upper tract urothelial carcinoma: does the location matter?
J Endourol
. 2017 Mar
;31
(3
):259
–65
. .28.
Sung
HH
, Jeon
HG
, Han
DH
, Jeong
BC
, Seo
SI
, Lee
HM
, et al. Diagnostic ureterorenoscopy is associated with increased intravesical recurrence following radical nephroureterectomy in upper tract urothelial carcinoma
. PLoS One
. 2015
;10
(11
):e0139976
. .29.
Guo
RQ
, Hong
P
, Xiong
GY
, Zhang
L
, Fang
D
, Li
XS
, et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcimas on oncological outcomes: a meta-analysis
. BJU Int
. 2018 Feb
;121
(2
):184
–93
.30.
Marchioni
M
, Primiceri
G
, Cindolo
L
, Hampton
LJ
, Grob
MB
, Guruli
G
, et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis
. BJU Int
. 2017 Sep
;120
(3
):313
–9
. .31.
Lee
JK
, Kim
KB
, Park
YH
, Oh
JJ
, Lee
S
, Jeong
CW
, et al. Correlation between the timing of diagnostic ureteroscopy and intravesical recurrence in upper tract urothelial cancer
. Clin Genitourin Cancer
. 2016
;14
(1
):e37
–41
. .32.
Sankin
A
, Tin
AL
, Mano
R
, Chevinsky
M
, Jakubowski
C
, Sfakianos
JP
, et al. Impact of ureteroscopy before nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes
. Urology
. 2016 Aug
;94
:148
–53
. .© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
